Medicine shortages 1 |1 | P ROGRESS AND FUTURE AGENDA M EDICINES SHORTAGES IN MANUFACTURING " GLOBAL STOCK OUTS " Department of Essential Medicines and.

Slides:



Advertisements
Similar presentations
JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
Advertisements

1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Medicines Prices and Methods of Financing in South-East Asia Indian Pharmacological Society 38 th Annual Conference, Chennai 29th December 2005 Dr K Weerasuriya,
Group III: Demand Forecasting
Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.
Global impact of medicine shortages Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Toronto, Canada June.
FRESENIUS KABI SOUTHERN AFRICAN EXPERIENCE
Authors: Rene Soria-Saucedo 1, Veronika J. Wirtz 1, Warren A. Kaplan 2 Institutions: 1 Center for Health Systems Research, National Institute of Public.
Workshop 2 Supply reasons Solutions for medicines shortages.
RMNCH Medicines in Every Woman Every Child Countries Survey results on Regulatory and Procurement Status Lisa Hedman Deus Mubangizi Robinah Najjemba World.
Critical Drug Shortages: A Major Public Health Problem That Affects Us All and How To Deal With It Philip M. Rosoff, M.D., M.A. Professor of Pediatrics.
COA Patient Advocacy Network Drug Shortages, Oral Chemotherapy Orlando, Community Oncology Alliance.
APIs – global business developments Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President, B&P Development Srl,
Management of Medicines and Pharmaceutical Supplies for use in the prevention and treatment of Pre-eclampsia and Eclampsia Grace Adeya, SPS/MSH February.
USAID Update 2014 Bureau for Global Health Christine Malati, PharmD
1 |1 | Prequalification Programme – Stakeholders Meeting Geneva, February 2010 Access to Assured-Quality Praziquantel for the Control of Human Schistosomiasis.
Measles Partnership Meeting Yalda Momeni September 23 rd - WDC.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
Dr K N Prasad Community Medicine
Demand Policy for Innovation The Australian Experience
CBI - Ministry of Foreign Affairs Translating industry trends for health products to natural ingredients.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
Activities and plans at WHO Headquarters Godfrey C Xuereb Team Leader Population-based Prevention Team SPP Unit Department of Chronic Diseases and Health.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
Contact Monitoring Regional Network (CMKN). Why procurement It is estimated that an effective public procurement system could save as much as 25% of government.
RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.
Overviews of the Drug Distribution System & Barriers to Opioid Availability Dr. Bishnu Dutta Paudel International Pain Policy Fellowship Training Program.
ACCESS TO MEDICINES - POLICY AND ISSUES
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
CO “All-Ukrainian Network of People Living with HIV” Potential Problems in Supply – What Can Be Done? Kyiv, 2008.
Yemaneberhan Taddesse.  PASDEP(plan of accelerated and sustainable development for the Eradication of poverty) Poverty reduction strategy is the main.
AMC Governance and Institutional Support. Objectives Build on existing capacity Ensure appropriate independence and credibility through transparency,
Quantification of Antimalarials PSM Workshop Nairobi, Kenya February 21, 2006.
Strengthening the impact of the WHO prequalification program April 28, 2007.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Copyright © 2015 Cengage Learning® Chapter 9 Parenteral Medication Labels and Dosage Calculation.
Representative Office, I.R. Iran Iodine Deficiency: A Global Challenge.
Market Research on 2015 Global Zinc Citrate Market Key Manufacturing Analysis Report Published: Oct 2015 Single User License: US $2800 Corporate User License:
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
Outcome On completion of this unit the student should be able to describe and evaluate programs implemented by international and Australian government.
Market Research on Global Wheat Germ Oil Industry Trends Survey and Opportunities Report Published: Nov 2015 Single User License: US $2800 Corporate.
TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.
Key Issues from DAY 2 31 st January 2006 Jane Masiga & Val Remedios.
The Oncology Drug Shortage
Copyright © 2015 Cengage Learning® Chapter 9 Parenteral Medication Labels and Dosage Calculation.
3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.
Global Alfalfa Oil Industry - Size, Share and Market Forecasts 2021
Global Avocado Oil Industry 2016 Market Research Report
Global Benzalkonium Chloride Industry Analysis and Revenue Forecast 2016
China Zinc Citrate Market Forecasts to 2021
RISK FACTORS FOR MALNUTRITION
Copyright © 2010 Delmar, Cengage Learning. ALL RIGHTS RESERVED. Chapter 9 Parenteral Medication Labels and Dosage Calculation.
IPC, Washington DC, June |1 | Update to the IPC WHA resolutions on shortages Update to the IPC WHA resolutions on shortages Lisa Hedman June 2016.
1 |1 | Quality of Active Pharmaceutical Ingredients Beijing, 31 March 2010 Access to Assured-Quality Praziquantel for the Control of Human Schistosomiasis.
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
Peripheral IV Infiltration Tool
1ST International High Level Multi-Stakeholders Meeting on Promoting Pharmaceutical Sector Investments in the East African Community (EAC) Region   NAIROBI.
Inter-Agency Guidelines for Good Procurement of Pharmaceuticals
CQA Certified Quality Auditor
Bayer - Supply Chain Management
World Health Organization
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies Introduction and Overview May 30 to June 4, 2005 Abuja, Nigeria.
Regulation of Medical Products & Patient Safety- A Narrative Review
Dairying in Asia: Strategic opportunities, challenges and the response
Practical methods for reducing stockholding
Private Sector: Who is Accountable?
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Multi-Stakeholder Collaboration in Support of Local Production of Pharmaceuticals (LPP) Mr. Godfrey Keele, MPharm (UNIDO) HRDC Summit, 29 March 2016,
Presentation transcript:

Medicine shortages 1 |1 | P ROGRESS AND FUTURE AGENDA M EDICINES SHORTAGES IN MANUFACTURING " GLOBAL STOCK OUTS " Department of Essential Medicines and Health Products Lisa Hedman

Medicine shortages 2 |2 | Defined as shortages or stock outs caused by manufacturing insufficiency Similar incidence between branded versus generics Higher incidence in older g enerics, sterile injectables, oncology medicines Affects countries of all income levels Can be confused with supply chain stock outs in some situations Overview of global stock outs

Medicine shortages 3 |3 | Increasing trend United States Food and Drug Administration accessed 22 October l Example of trends from USA

Medicine shortages 4 |4 | Deferoxamine Mesylate for Injection (Desferal) (Discontinuation) Deferoxamine Mesylate for Injection (Desferal) Denileukin Diftitox (Ontak) Injection (Discontinuation) Denileukin Diftitox (Ontak) Injection Doxorubicin (Adriamycin) Injection (Shortage) Doxorubicin (Adriamycin) Injection Ethiodized Oil (Lipiodol) Injection (Shortage) Ethiodized Oil (Lipiodol) Injection Leucovorin Calcium Lyophilized Powder for Injection (Shortage) Leucovorin Calcium Lyophilized Powder for Injection Leuprolide Acetate Injection (Shortage) Leuprolide Acetate Injection Mesna Injection (Discontinuation) Mesna Injection Ondansetron (Zofran) Injection (Discontinuation) Ondansetron (Zofran) Injection Thiotepa (Thioplex) for Injection (Shortage) Thiotepa (Thioplex) for Injection Tositumomab and Iodine I 131 Tositumomab (Bexxar) (Discontinuation) Tositumomab and Iodine I 131 Tositumomab (Bexxar) Current oncology medicines shortages USFDA 28 October 2015: drugshortages/default.cfm

Medicine shortages 5 |5 | Ammonium Chloride InjectionAmmonium Chloride Injection (Shortage) Atropine Sulfate InjectionAtropine Sulfate Injection (Shortage) Atropine Sulfate InjectionAtropine Sulfate Injection (Discontinuation) alcium Chloride Injection, USPalcium Chloride Injection, USP (Shortage) Calcium Gluconate InjectionCalcium Gluconate Injection (Shortage) Cefazolin InjectionCefazolin Injection (Shortage) Cefepime InjectionCefepime Injection (Shortage) Cefotaxime Sodium (Claforan) Injection Cefotaxime Sodium (Claforan) Injection (Shortage) Chloramphenicol Sodium Succinate Injection Chloramphenicol Sodium Succinate Injection (Shortage) Chloroquine Phosphate TabletsChloroquine Phosphate Tablets (Shortage) Cidofovir InjectionCidofovir Injection (Discontinuation) Dexamethasone Sodium Phosphate Injection Dexamethasone Sodium Phosphate Injection (Shortage) Dextrose 5% Injection BagsDextrose 5% Injection Bags (Shortage) Doxorubicin (Adriamycin) Injection Doxorubicin (Adriamycin) Injection (Shortage) Epinephrine 1mg/mL (Preservative Free) Epinephrine 1mg/mL (Preservative Free) 23 (Shortage) Epinephrine InjectionEpinephrine Injection (Shortage) Current shortages: Dosage forms for children Fentanyl Citrate (Sublimaze) Injection Fentanyl Citrate (Sublimaze) Injection (Shortage) Leucovorin Calcium Lyophilized Powder for InjectionLeucovorin Calcium Lyophilized Powder for Injection (Shortage) Leuprolide Acetate InjectionLeuprolide Acetate Injection (Shortage) Levetiracetam (Keppra) InjectionLevetiracetam (Keppra) Injection (Shortage) Lidocaine Hydrochloride (Xylocaine) Injection Lidocaine Hydrochloride (Xylocaine) Injection (Shortage) Liotrix (Thyrolar) TabletsLiotrix (Thyrolar) Tablets (Shortage) Lorazepam (Ativan) Injection Lorazepam (Ativan) Injection (Discontinuation) Magnesium Sulfate InjectionMagnesium Sulfate Injection (Shortage) Mecasermin [rDNA origin] (Increlex) Injection Mecasermin [rDNA origin] (Increlex) Injection (Shortage) Meloxicam (Mobic) Oral Suspension Meloxicam (Mobic) Oral Suspension (Discontinuation) Meropenem for Injection, USPMeropenem for Injection, USP (Shortage) Methyldopate Hydrochloride Injection Methyldopate Hydrochloride Injection (Shortage) Methylin Chewable TabletsMethylin Chewable Tablets (Shortage) Methylphenidate Hydrochloride ER Capsules/Tablets Methylphenidate Hydrochloride ER Capsules/Tablets 24 (Shortage) Ondansetron (Zofran) Injection Ondansetron (Zofran) Injection (Discontinuation) Pancuronium Bromide InjectionPancuronium Bromide Injection (Shortage) Peritoneal Dialysis SolutionsPeritoneal Dialysis Solutions (Shortage) Piperacillin and Tazobactam (Zosyn) InjectionPiperacillin and Tazobactam (Zosyn) Injection (Shortage) Potassium Chloride InjectionPotassium Chloride Injection (Shortage) Reserpine TabletsReserpine Tablets (Shortage) Sodium Chloride 0.9% Injection Bags Sodium Chloride 0.9% Injection Bags (Shortage) Sodium Chloride 23.4% Injection Sodium Chloride 23.4% Injection (Shortage) Sodium Chloride 23.4% Injection Sodium Chloride 23.4% Injection (Discontinuation) Sufentanil Citrate (Sufenta) Injection Sufentanil Citrate (Sufenta) Injection (Shortage) Thiotepa (Thioplex) for InjectionThiotepa (Thioplex) for Injection (Shortage) Tiopronin (Thiola)Tiopronin (Thiola) (Shortage) Tobramycin InjectionTobramycin Injection (Shortage) Trace ElementsTrace Elements (Shortage) Vancomycin Hydrochloride for Injection, USPVancomycin Hydrochloride for Injection, USP (Shortage) USFDA 28 October 2015: drugshortages/default.cfm

Medicine shortages 6 |6 | Regulatory decisions e.g., plant closures Insufficient manufacturing base (3 or fewer manufacturers) Market failures, including unaffordability and low-margins Competition for production capacity with higher margin products Poor visibility into demand cycles Less than full batch order quantities Poor procurement practices, eg payment and other terms Most commonly cited causes

Medicine shortages 7 |7 | Advance reporting to regulatory agencies from manufacturers Fast track regulatory assessments to manage risk of substitution Programmatic and association based reporting Compulsory licenses (eg for ARVs) Contract penalties in procurement Solutions in use for national level management

Medicine shortages 8 |8 | Who benefits from early warning systems of stringent regulatory authorities

Medicine shortages 9 |9 | Case study: global shortage of benzathine penicillin (PenG) WHO quantification in 20 countries with highest syphilis burden –4 million doses (in 2.4 MU) for adult men and women with early stage syphilis 1 and for pregnant women with active syphilis –90,000 doses of 3.8 MU for infants with premature delivery due to syphilis and infants with congenital syphilis Pen G and rheumatic heart disease –Up to 20 million doses needed for acute RH disease and continuing treatment –figures unreliable due to poor Dx, Rx and medicine consumption data Global supply is insufficient with 3 producers and repeated non- availability reports by major procurers 1 Assumptions and calculations are preliminary data from pending WHO analysis

Medicine shortages 10 | Global advance reporting systems for medicines at high risk ie manufacturers report in advance Fast track options to manage risk of substitutions along with communication approaches Harmonization of fast track regulatory reviews with information sharing Forums to identify and monitor highest risk products Model policy and legislation to promote effective management Solutions and conclusions of the meeting on managing and preventing global stock outs

Medicine shortages 11 | Regularize pricing policy to ensure that production can be realistically sustained Engage in prioritization and include models used by industry in the discussion Paradigm shifts needed in supply chain, motivation to report, and transparency In supply chain, development and exchange of quality information will take major changes –Implementation of GS1 bar coding systems as a starting point Solutions and conclusions of the meeting on managing and preventing global stock outs

Medicine shortages 12 | Photo: Dr Charles Senessie, SwissmedIc Thank you to all Thank you